Hepatitis C virus kinetics during the first phase of pegylated interferon-α-2b with ribavirin therapy in patients with living donor liver transplantation

Hepatology Research

Volumn 39, Issue 9, 2009, Pages 856-864

  Ichikawa, Tatsuki ^a   Nakao, Kazuhiko ^a   Miyaaki, Hisamitsu ^a   Eguchi, Susumu ^a   Takatsuki, Mitsuhisa ^a   Fujimito, Masumi ^a   Akiyama, Motohisa ^a   Miuma, Satoshi ^a   Ozawa, Eisuke ^a   Shibata, Hidetaka ^a   Takeshita, Shigeyuki ^a   Kanematsu, Takashi ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; First phase; Hepatitis C virus; Interferon; Living donor liver transplantation

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS CORE ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; PRIORITY JOURNAL; SEROTYPE; TREATMENT RESPONSE; VIRUS CORE; VIRUS LOAD;

EID: 69949084331     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00524.x     Document Type: Article

References (30)

1. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis b virus and hepatitis c virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
2. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
3. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
4. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673-84.
5. Carrion JA, Navasa M, Garcia-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746-56.
6. Davis GL, Wong JB, McHutchison JG et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
7. Fernandez I, Meneu JC, Colina F et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-12.
8. Hu X, Li WP, Meng C et al. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 2003; 170: 4833-9.
9. Boor PP, Metselaar HJ, Mancham S et al. Prednisolone suppresses the function and promotes apoptosis of plasmacytoid dendritic cells. Am J Transpl 2006; 6: 2332-41.
10. Hirano K, Ichikawa T, Nakao K et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporine A, on interferon induced anti-viral protein in human hepatocyte cell. Liver Transpl 2008; 14: 295-301.
11. Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-63.
12. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
13. Desmet VJ, Gerber M, Hoofnagle JH et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
14. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
15. Gonzalez V, Padilla E, Diago M et al. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin. J Viral Hepat 2005; 12: 481-7.
16. Taura N, Ichikawa T, Hamasaki K et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006; 101: 2752-9.
17. Taliani G, Gemignani G, Ferrari C et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130: 1098-106.
18. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7.
19. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40: 368-74.
20. Mook S, Halkes CJ C, Bilecen S et al. In vivo regulation of plasma free fatty acids in insulin resistance. Metabolism 2004; 53: 1197-201.
21. Kronenberger B, Herrmann E, Micol F et al. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40: 1442-9.
22. Delgado-Borrego A, Casson D, Schoenfeld D et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703-10.
23. Bloom RD, Lake JR. Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transpl 2006; 6: 2232-7.
24. Ichikawa T, Nakao K, Nakata K et al. Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. Biochem Biophys Res Commun 2002; 294: 414-22.
25. Oprescu AI, Bikopoulos G, Naassan A et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: Evidence for a role of oxidative stress in vitro and in vivo. Diabetes 2007; 56: 2927-37.
26. Tripathy D, Mohanty P, Dhindsa S et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-7.
27. Di Bona D, Cippitelli M, Fionda C et al. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 2006; 45: 271-9.
28. Layden JE, Layden TJ, Reddy KR et al. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002; 9: 340-5.
29. Boulestin A, Kamar N, Sandres-Saune K et al. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Med Virol 2006; 78: 365-71.
30. Smith MW, Walters KA, Korth MJ et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006; 130: 179-87.